Hainan Haiyao (000566.SZ): Injectable meropenem passed the consistent evaluation of generic drug quality and efficacy

According to the Zhitong Finance App, Hainan Haiyao (000566.SZ) issued an announcement. Haikou Pharmaceutical Factory Co., Ltd., a wholly-owned subsidiary of the company, recently obtained approval from the State Drug Administration to issue a “Drug Supplement Application Approval Notice” for injectable chemical meropenem.

Meropenem is an artificially synthesized broad-spectrum carbapenem antibiotic. By inhibiting the synthesis of bacterial cell walls, meropenem easily penetrates the cell wall of most gram-positive and negative bacteria to reach its target penicillin-binding proteins (PBPs). In addition to metal beta-lactamase, it has a strong hydrolytic effect on most beta-lactamases (including penicillinase and cephalosporase produced by gram-positive bacteria and gram-negative bacteria).

Injectable meropenem is mainly suitable for infections in adults and children caused by a single or multiple bacteria sensitive to meropenem: pneumonia (including hospital-acquired pneumonia), urinary tract infections, intra-abdominal infections, gynecological infections (such as endometritis and pelvic inflammation), skin and soft tissue infections, meningitis, and sepsis.